Chunghwa Chemical Synthesis & Biotech Co Ltd (CCSB, 中化合成生技) yesterday said that it is ready to produce remdesivir, an experimental antiviral drug being studied as a treatment for COVID-19, if the government determines that it is safe and effective against the novel coronavirus that causes the disease.
The company earlier this week completed the synthesis of 4.73g of remdesivir with a purity of 99.72 percent.
“We spent about two weeks replicating the drug. The synthesis part was not time-consuming, but we spent some time waiting for ingredients from abroad,” CCSB spokesman Eason Wang (王冠傑) told the Taipei Times by telephone.
The company purchased the processed ingredients from overseas, as it lacks low-temperature equipment to proceed with synthesis, he said.
“As some chemical reactions have to take place at a very low temperature — about minus-78°C — when combining the compounds to make remdesivir, a special device is necessary,” Wang said, adding that the firm is considering buying such equipment to enable full production.
CCSB, a manufacturer of active pharmaceutical ingredients, was the latest local institution or company to succeed in replicating the experimental drug after Academia Sinica and Formosa Laboratories Inc (台耀化學).
Remdesivir, developed by US-based Gilead Sciences Inc, has shown promising results in fighting the novel coronavirus in an early analysis of overseas studies, Wang said.
Taiwan is also conducting clinical trials to test the drug’s efficacy, he said.
As no definitive conclusion on whether remdesivir is an effective treatment for COVID-19 has been made and Gilead has a patent for the drug, CCSB does not plan to mass-produce it, unless the government makes it compulsory for local companies to produce such drugs, Wang said.
With a stable supply of ingredients from overseas, CCSB could manufacture 30kg of remdesivir within 12 weeks, which should be enough to treat 30,000 patients, who would each need about 1.1g, he said.
“As the spread of COVID-19 seems to have abated in Taiwan,” with the Central Epidemic Command Center yesterday reporting zero new cases for the third time this week, “we do not expect high demand for the drug domestically,” Wang said.
However, local regulators might consider allowing companies to produce the drug to help other nations deal with escalating outbreaks of the disease, as the government earlier this month donated masks to affected countries, he said.
WEAKER ACTIVITY: The sharpest deterioration was seen in the electronics and optical components sector, with the production index falling 13.2 points to 44.5 Taiwan’s manufacturing sector last month contracted for a second consecutive month, with the purchasing managers’ index (PMI) slipping to 48, reflecting ongoing caution over trade uncertainties, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The decline reflects growing caution among companies amid uncertainty surrounding US tariffs, semiconductor duties and automotive import levies, and it is also likely linked to fading front-loading activity, CIER president Lien Hsien-ming (連賢明) said. “Some clients have started shifting orders to Southeast Asian countries where tariff regimes are already clear,” Lien told a news conference. Firms across the supply chain are also lowering stock levels to mitigate
NEW PRODUCTS: MediaTek plans to roll out new products this quarter, including a flagship mobile phone chip and a GB10 chip that it is codeveloping with Nvidia Corp MediaTek Inc (聯發科) yesterday projected that revenue this quarter would dip by 7 to 13 percent to between NT$130.1 billion and NT$140 billion (US$4.38 billion and US$4.71 billion), compared with NT$150.37 billion last quarter, which it attributed to subdued front-loading demand and unfavorable foreign exchange rates. The Hsinchu-based chip designer said that the forecast factored in the negative effects of an estimated 6 percent appreciation of the New Taiwan dollar against the greenback. “As some demand has been pulled into the first half of the year and resulted in a different quarterly pattern, we expect the third quarter revenue to decline sequentially,”
Six Taiwanese companies, including contract chipmaker Taiwan Semiconductor Manufacturing Co. (TSMC), made the 2025 Fortune Global 500 list of the world’s largest firms by revenue. In a report published by New York-based Fortune magazine on Tuesday, Hon Hai Precision Industry Co. (better known as Foxconn) ranked highest among Taiwanese firms, placing 28th with revenue of US$213.69 billion. Up 60 spots from last year, TSMC rose 60 places to reach No. 126 with US$90.16 billion in revenue, followed by Quanta Computer Inc. at 348th, Pegatron Corp. at 461st, CPC Corp., Taiwan at 494th and Wistron Corp. at 496th. According to Fortune, the world’s
DIVERSIFYING: Taiwanese investors are reassessing their preference for US dollar assets and moving toward Europe amid a global shift away from the greenback Taiwanese investors are reassessing their long-held preference for US-dollar assets, shifting their bets to Europe in the latest move by global investors away from the greenback. Taiwanese funds holding European assets have seen an influx of investments recently, pushing their combined value to NT$13.7 billion (US$461 million) as of the end of last month, the highest since 2019, according to data compiled by Bloomberg. Over the first half of this year, Taiwanese investors have also poured NT$14.1 billion into Europe-focused funds based overseas, bringing total assets up to NT$134.8 billion, according to data from the Securities Investment Trust and Consulting Association (SITCA),
RSS